Barclays upgraded Medpace (MEDP) to Equal Weight from Underweight with an unchanged price target of $500. The firm cites valuation for the upgrade. Medpace continues to win business and potential disruption from faster burning business rolling off fis likely to be much more limited in scale than imagined, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: